CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial.

purposeHypopharyngeal squamous cell carcinoma (HPSCC) has a poor prognosis. Although neoadjuvant chemoimmunotherapy (nCIT) is promising, responses are heterogeneous, and the PD-L1 combined positive score (CPS) inadequately stratifies benefit. We sought biomarkers to guide patient selection. PATIENTS AND

methodsIn this prospective, single-center, single-arm phase II trial, patients with resectable locally advanced HPSCC received two cycles of neoadjuvant toripalimab, albumin-bound paclitaxel, and nedaplatin. The primary endpoint was the pathologic complete response (pCR) rate. Pretreatment tumor biopsies from a subset of patients (n = 13) were analyzed by single-cell RNA sequencing to identify determinants of response. Findings were validated in a larger cohort (n = 60) using bulk RNA-seq and immunohistochemistry.

resultsAmong 70 evaluable patients, the objective response rate was 82.7%. Of the 64 patients who underwent surgery, the pCR rate was 29.7% (95% confidence interval, 18.9%-42.7%). Baseline PD-L1 CPS was not associated with pathologic response (P = 0.313). Single-cell analysis revealed that the pretreatment tumor microenvironment of responders was significantly enriched with a proinflammatory neutrophil subset characterized by high expression of CCL3 (Neu_CCL3). A gene signature score derived from this subset was a strong and independent predictor of pCR (AUC = 0.788), significantly outperforming PD-L1 CPS (AUC = 0.621).

conclusionsThe efficacy of nCIT in HPSCC is predetermined by a baseline immune architecture orchestrated by a CCL3+ neutrophil subset. The Neu_CCL3 gene signature is a promising, clinically translatable biomarker that can fill a critical gap in precision immunotherapy for HPSCC.